Elevance Health (ELV)
Market Price (12/4/2025): $331.4 | Market Cap: $74.0 BilSector: Health Care | Industry: Managed Health Care
Elevance Health (ELV)
Market Price (12/4/2025): $331.4Market Cap: $74.0 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
Valuation, Metrics & Events
ELV Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are five key points explaining the approximate 4.4% movement in Elevance Health (ELV) stock from August 31, 2025, to December 4, 2025:
1. Elevance Health announced strategic shifts and a revised 2025 earnings outlook in early September. The company revealed plans to exit standalone Medicare Part D and scale back underperforming Medicare Advantage markets. Concurrently, it adjusted its full-year 2025 adjusted earnings per share (EPS) outlook to approximately $30, a reduction from the prior range of $34.15-$34.85, citing rising medical costs as a contributing factor. This revised guidance likely exerted downward pressure on the stock.
2. Concerns over potential tariffs on medical equipment impacted the stock in late September. Elevance Health's shares experienced a decline after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices. This probe raised concerns among investors about the possibility of new tariffs, which could increase costs across the healthcare sector.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELV Return | 8% | 46% | 12% | -7% | -21% | -9% | 18% |
| Peers Return | 18% | 32% | 14% | -3% | -18% | -25% | 5% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| ELV Win Rate | 58% | 58% | 50% | 33% | 67% | 60% | |
| Peers Win Rate | 50% | 55% | 58% | 48% | 42% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| ELV Max Drawdown | -42% | -10% | -8% | -19% | -21% | -25% | |
| Peers Max Drawdown | -32% | -6% | -14% | -21% | -24% | -37% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: UNH, CI, HUM, CNC, MOH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | ELV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -24.3% | -25.4% |
| % Gain to Breakeven | 32.0% | 34.1% |
| Time to Breakeven | 310 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.2% | -33.9% |
| % Gain to Breakeven | 76.2% | 51.3% |
| Time to Breakeven | 214 days | 148 days |
| 2018 Correction | ||
| % Loss | -25.6% | -19.8% |
| % Gain to Breakeven | 34.4% | 24.7% |
| Time to Breakeven | 567 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -67.2% | -56.8% |
| % Gain to Breakeven | 204.8% | 131.3% |
| Time to Breakeven | 1821 days | 1480 days |
Compare to UNH, CI, HUM, CNC, MOH
In The Past
Elevance Health's stock fell -24.3% during the 2022 Inflation Shock from a high on 10/31/2022. A -24.3% loss requires a 32.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to ELV. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Elevance Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | - |
| Mkt Cap | - |
| Rev LTM | - |
| Op Inc LTM | - |
| FCF LTM | - |
| FCF 3Y Avg | - |
| CFO LTM | - |
| CFO 3Y Avg | - |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | - |
| P/S | - |
| P/EBIT | - |
| P/E | - |
| P/CFO | - |
| Total Yield | - |
| Dividend Yield | - |
| FCF Yield 3Y Avg | - |
| D/E | - |
| Net D/E | - |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | - |
| 3M Rtn | - |
| 6M Rtn | - |
| 12M Rtn | - |
| 3Y Rtn | - |
| 1M Excs Rtn | - |
| 3M Excs Rtn | - |
| 6M Excs Rtn | - |
| 12M Excs Rtn | - |
| 3Y Excs Rtn | - |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Health Benefits | 148,571 | 138,484 | |||
| CarelonRx | 33,835 | 28,526 | 25,431 | 10,384 | 2,007 |
| Carelon Services | 14,147 | 12,860 | |||
| Net investment income | 1,825 | 1,485 | 1,378 | 877 | 1,005 |
| Corporate & Other | 479 | 399 | |||
| Net losses on financial instruments | -694 | -550 | 318 | 182 | 67 |
| Eliminations | -26,823 | -24,609 | -20,466 | ||
| Commercial and Specialty Business | 38,809 | 36,699 | 37,421 | ||
| Government Business | 82,919 | 71,572 | 62,632 | ||
| Other | 10,250 | 2,153 | 1,081 | ||
| Total | 171,340 | 156,595 | 138,639 | 121,867 | 104,213 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10212025 | 10-Q 9/30/2025 |
| 6302025 | 7172025 | 10-Q 6/30/2025 |
| 3312025 | 4222025 | 10-Q 3/31/2025 |
| 12312024 | 2202025 | 10-K 12/31/2024 |
| 9302024 | 10172024 | 10-Q 9/30/2024 |
| 6302024 | 7172024 | 10-Q 6/30/2024 |
| 3312024 | 4182024 | 10-Q 3/31/2024 |
| 12312023 | 2212024 | 10-K 12/31/2023 |
| 9302023 | 10182023 | 10-Q 9/30/2023 |
| 6302023 | 7192023 | 10-Q 6/30/2023 |
| 3312023 | 4192023 | 10-Q 3/31/2023 |
| 12312022 | 2152023 | 10-K 12/31/2022 |
| 9302022 | 10192022 | 10-Q 9/30/2022 |
| 6302022 | 7202022 | 10-Q 6/30/2022 |
| 3312022 | 4202022 | 10-Q 3/31/2022 |
| 12312021 | 2162022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | DeVore Susan D. | 8212025 | Buy | 312.15 | 1,200 | 374,580 | 1,093,149 | Form | |
| 1 | BOUDREAUX GAIL | President and CEO | 7182025 | Buy | 286.07 | 2,334 | 667,687 | 41,438,384 | Form |
| 2 | Kaye Mark | EVP & CFO | 4252025 | Sell | 424.82 | 4,588 | 1,949,074 | 8,061,809 | Form |
| 3 | Penczek Ronald W | CAO & Controller | 3112025 | Sell | 415.13 | 443 | 183,903 | 766,745 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |